Oligometastatic Prostate Cancer Clinical Trials

7 recruiting

Oligometastatic Prostate Cancer Trials at a Glance

10 actively recruiting trials for oligometastatic prostate cancer are listed on ClinicalTrialsFinder across 6 cities in 26 countries. The largest study group is Phase 2 with 4 trials, with the heaviest enrollment activity in Tel Aviv, Shanghai, and New York. Lead sponsors running oligometastatic prostate cancer studies include Catherine Spina, Centro di Riferimento Oncologico - Aviano, and British Columbia Cancer Agency.

Browse oligometastatic prostate cancer trials by phase

Treatments under study

About Oligometastatic Prostate Cancer Clinical Trials

Looking for clinical trials for Oligometastatic Prostate Cancer? There are currently 7 studies actively recruiting participants. Clinical trials offer access to new treatments before they are widely available, and every approved therapy in use today was first tested through a clinical trial.

Below you can browse trials, sign up for alerts when new Oligometastatic Prostate Cancer trials open, and view eligibility criteria for each study. Each listing includes the study phase, locations, and enrollment details.

Frequently Asked Questions

Common questions about Oligometastatic Prostate Cancer clinical trials

A clinical trial is a carefully designed research study that tests new medical treatments, drugs, devices, or approaches in human volunteers. Every approved medication and treatment available today was proven safe and effective through clinical trials.

All clinical trials are reviewed and approved by Institutional Review Boards (IRBs) — independent committees that evaluate patient safety. Trials follow strict protocols, and your health is monitored closely throughout. You can withdraw at any time.

Not necessarily. Many trials compare the new treatment against the current standard of care, meaning all participants receive active treatment. When placebos are used, they are typically combined with standard treatment, not given alone. The trial description will always specify the design.

Under the Affordable Care Act, most private insurers are required to cover routine patient care costs during a clinical trial. The sponsor typically covers the investigational treatment itself. Medicare also covers routine costs for qualifying trials.

Yes. Participation is completely voluntary. You can withdraw at any time, for any reason, without it affecting your access to standard medical care.

Each trial has specific eligibility criteria — including age, diagnosis, disease stage, prior treatments, and general health. Browse the trials listed above and check their eligibility sections. You can also contact the trial site directly to discuss your situation.

Showing 110 of 10 trials

Recruiting
Phase 3

An Open-label Study Comparing Lutetium (177Lu) Vipivotide Tetraxetan Versus Observation in PSMA Positive OMPC.

Oligometastatic Prostate Cancer (OMPC)
Novartis Pharmaceuticals450 enrolled142 locationsNCT05939414
Recruiting
Phase 1

Trial of pTVG-HP+Nivo+Targeted Ablation of Resistant Lesions in Non-Castrate RecurrentOMPC

Prostate Cancer PatientsRecurrent Prostate CancerOligometastatic Prostate Cancer (OMPC)+1 more
University of Wisconsin, Madison14 enrolled1 locationNCT07090148
Recruiting
Not Applicable

5500/20 vs. SABR or Brachytherapy for PRimary OligoMetastatic Prostate Cancer Treatment (PROMPT)

Oligometastatic Prostate Cancer
British Columbia Cancer Agency168 enrolled4 locationsNCT04610372
Recruiting
Not Applicable

Comprehensive Versus Primary Tumor Radiotherapy in Oligometastatic Prostate Cancer

Prostate CancerOligometastatic Prostate Cancer
Peking University First Hospital390 enrolled3 locationsNCT07015138
Recruiting
Phase 2

Lu-PSMA for Oligometastatic Prostate Cancer Treated With STereotactic Ablative Radiotherapy

Oligometastatic Prostate Cancer
Peter MacCallum Cancer Centre, Australia92 enrolled3 locationsNCT05560659
Recruiting
Phase 2

Adenosine Signaling Modulation and Immune Checkpoint Inhibition With Hormone Sensitive Oligometastatic Prostate Cancer

Oligometastatic Prostate Cancer
Catherine Spina23 enrolled1 locationNCT05915442
Recruiting
Phase 2Phase 3

Maximal Tumor Eradication for Oligometastatic Prostate Cancer

Oligometastatic Prostate Cancer
RenJi Hospital120 enrolled1 locationNCT06972511
Recruiting
Phase 2

Genomic Biomarker-guided Neoadjuvant Therapy for Prostate Cancer (SEGNO)

Locally Advanced Prostate CancerOligometastatic Prostate Cancer
The First Affiliated Hospital of Xiamen University40 enrolled1 locationNCT06387056
Recruiting
Not Applicable

An Evaluation of the Efficacy and Safety of Apalutamide as Neoadjuvant Endocrine Therapy in High-Risk and Oligometastatic Prostate Cancer

High-Risk and Oligometastatic Prostate Cancer
Zhujiang Hospital50 enrolled1 locationNCT04997252
Recruiting

Prostate Oligometastatic Cancer Management Driven by Disease Biology et/or Immunoactivity (PROMETEO)

Oligometastatic Prostate Cancer
Centro di Riferimento Oncologico - Aviano104 enrolled2 locationsNCT06060652